Intelligent Bio Solutions has initiated a validation study to cut the analysis time of its Intelligent Fingerprinting Drug Screening System from roughly 10 minutes to under three minutes, with sample collection already completed in under a minute. The program targets a two-minute readout, positioning the fingerprint-based, point-of-collection assay for roadside drug screening and other time-sensitive settings. The U.S. roadside testing market was estimated at $1.17 billion in 2023 and is projected to reach $1.62 billion by 2030, while the broader global drug screening market is forecast to top $16.7 billion over the same period.
The core move is operational rather than clinical: INBS is validating whether it can materially compress time-to-result without sacrificing field performance, a requirement for adoption in law enforcement workflows. The system is currently restricted to Forensic Use Only in the U.S. The company is pursuing FDA 510(k) clearance for codeine detection to open broader use beyond FEO, with speed as a central feature for roadside deployment and a potential wedge into adjacent markets including workplace safety, criminal justice supervision, and substance use treatment. The study is in a preliminary phase.
Strategically, this is a speed play into a market constrained by throughput and evidentiary expectations. Roadside drug screening today relies largely on saliva-based kits and offsite confirmation, with officer time and driver hold durations limiting volume. A sub-three-minute result could reduce stop times, improve officer safety, and increase screening capacity, but only if analytical performance remains credible under real-world conditions. That creates a clear tension: faster chemistry and simplified handling must still deliver acceptable sensitivity, specificity, and robustness against interferents and environmental variability. The 510(k) pathway for a single analyte suggests a stepwise clearance strategy, likely requiring sequential submissions to extend claims across an opioid panel and other drug classes — a pragmatic route but one that slows full-market competitiveness against established multi-analyte platforms.
For agencies and procurement teams, the operational calculus will hinge on validated accuracy, failure rates, training burden, and integration with chain-of-custody, confirmatory testing, and reporting systems. States setting policy after marijuana liberalization are looking for rapid, non-invasive tools, yet evidentiary acceptance varies and impairment standards for THC remain unsettled, potentially limiting roadside utility even if screens are fast. For clinical research networks and treatment programs, a hygienic, fingerprint-based assay with near-instant results could streamline intake, reduce staff time, and support higher-frequency monitoring without phlebotomy or observed urine collection. CROs running substance use and behavioral trials may see logistics advantages in community or home settings if performance data support decentralized use. Vendors in point-of-collection diagnostics should read this as further validation of a shift toward compact, operator-light systems that compress the time from specimen to action.
The next milestones to watch are hard data from the validation effort: distribution of time-to-result, concordance with lab confirmation, environmental stress testing, invalid/indeterminate rates, and performance across common prescription and illicit substances. On the regulatory front, clarity on the 510(k) review timeline for codeine and whether INBS moves quickly to expand claims to a broader panel will signal how aggressively the company intends to contest roadside tenders. Adoption will depend on pilot deployments with state patrols, total cost of ownership versus saliva kits, and evidence that speed gains do not come at the expense of accuracy. Policy developments on THC impairment thresholds and state-level evidentiary rules could either accelerate or cap market entry. The operational prize is clear; the risk is that speed alone will not overcome regulatory and performance bars that determine real-world procurement.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
